C. Diedrich
University of Lübeck
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C. Diedrich.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 1995
R. Felberbaum; Thomas Reissmann; W. Küpker; O. Bauer; Safaa Al Hasani; C. Diedrich; Klaus Diedrich
OBJECTIVE To examine the pituitary response in patients undergoing short-term application of the GnRH antagonist Cetrorelix in the mid-cycle phase for hypophysial suppression of premature LH surges within an IVF-program. DESIGN Twenty patients suffering from primary or secondary tubal infertility were stimulated with hMG from cycle day 2. From day 7 till ovulation induction Cetrorelix was administered in two different dose regimens (15 patients 3 mg s.c. daily; 5 patients 1 mg s.c. daily). Three hours before ovulation induction a GnRH test was performed using 25 micrograms of native GnRH and the pituitary response examined by measurement of the serum LH concentration after 30 min. RESULTS Premature LH surges could be avoided in the 3-mg group and in the 1-mg group, respectively. Due to this, none of the cycles had to be cancelled. Oestradiol profiles and ultrasound demonstrated a satisfactory follicular maturation. All patients showed pronounced suppression of the serum LH levels before ovulation induction. The mean increase of serum LH due to the performed GnRH test was 10 mIU/ml for the 3-mg group, while the average maximum in the 1-mg group was about 32.5 mIU/ml. CONCLUSIONS The pituitary response is preserved by the treatment with the GnRH antagonist Cetrorelix. The extent of suppression of the adenohypophysis, as expressed by the different reactions on GnRH test, can be modulated by the dosage administered. This should allow ovulation induction by GnRH or one of its agonists instead of hCG, which could be beneficial in patients at high risk of Ovarian Hyperstimulation Syndrome (OHSS) and those suffering from Polycystic Ovary Disease (PCOD).
Journal of Assisted Reproduction and Genetics | 1996
R. Felberbaum; T. Reissmann; W. Küpker; S. Al-Hasani; O. Bauer; T. Schill; C. Zoll; C. Diedrich; Klaus Diedrich
AbstractPurpose: The premature LH surge in ART programs seems to be avoided by daily administration of the GnRH-antagonist Cetrorelix during the midcycle phase in controlled ovarian hyperstimulation with hMG. The dosage necessary for sufficient suppression of the pituitary gland is not yet defined. Methods: To elucidate this question three daily dosages (3, 1, 0.5 mg) were administered and the hormone profiles obtained as well as the number of oocytes retrieved, the fertilization rate, and the consumption of HMG were compared. Results: No premature LH surge could be observed at any of the three dosages administered. Both gonadotropins were deeply suppressed. The fertilization rates of the oocytes obtained were 45.3% in the 3-mg group, 53.1% in the 1-mg group, and 67.7% in the 0.5-mg group. The average uses of hMG ampoules were 30 in the 3-mg group, 27 in the 1-mg group, and 26 in the 0.5-mg group. Conclusions: Cetrolix, 0.5 mg/day, administered during the midcycle phase of controlled ovarian hyperstimulation with hMG is enough to prevent completely the premature LH surge. Perhaps even lower dosages would be sufficient. Regarding fertilization rates and use of hMG, the lower dosage seems to be the most favorable.
Journal of Assisted Reproduction and Genetics | 1995
S.Al Hasani; W. Küpker; A.A. Baschat; R. Sturm; O. Bauer; C. Diedrich; K. Diedrich
PurposeThe male factor is nowadays one of the major problems in the treatment of infertility. New methods of assisted fertilization such as the intracytoplasmic sperm injection (ICSI) show better fertilization and pregnancy rates than classical IVF.MethodIn this study, we present a new technique of sperm preparation: the “mini-swim-up.”ConclusionThis technique, used in conjunction with the ICSI procedure, improves pregnancy and fertility rates in cases of severe oligoasthenoteratozoospermia.
Gynakologisch-geburtshilfliche Rundschau | 1995
R. Felberbaum; T. Reissmann; C. Zoll; W. Küpker; S. Al-Hasani; C. Diedrich; K. Diedrich
Fragestellung: Die Anwendbarkeit des GnRH-antagonisten Cetrorelix im Rahmen der kontrollierten ovariellen Hyperstimulation (COH) zur Vermeidung des vorzeitigen LH-Anstieges sollte u
Human Reproduction | 1994
K. Diedrich; C. Diedrich; E. Santos; C. Zoll; S. Al-Hasani; T. Reissmann; D. Krebs; D. Klingmüller
Human Reproduction | 1999
Monika Bals-Pratsch; S. Al-Hasani; B. Schöpper; C. Diedrich; Anne-Stefanie Hoepfner; J.M. Weiss; W. Küpker; R. Felberbaum; O. Ortmann; O. Bauer; Klaus Diedrich
Human Reproduction | 1988
Klaus Diedrich; C. Diedrich; Hans van der Ven; S. Al-Hasani; A. Werner; D. Krebs
Geburtshilfe Und Frauenheilkunde | 1999
J. M. Weiss; R. Felberbaum; P. Montzka; M. Ludwig; D. Strik; Monika Bals-Pratsch; S. Al-Hasani; O. Ortmann; C. Diedrich; K. Diedrich
Geburtshilfe Und Frauenheilkunde | 1994
K. Diedrich; C. Diedrich; Santos E; O. Bauer; Zoll C; S. Al-Hasani; Reissmann T; D. Krebs; Klingmüller D
Gynakologisch-geburtshilfliche Rundschau | 1995
R. Felberbaum; T. Reissmann; C. Zoll; W. Küpker; S. Al-Hasani; C. Diedrich; K. Diedrich